These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17009963)

  • 21. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
    Pérez-López ME; Curiel T; Gómez JG; Jorge M
    Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxaliplatin: a novel platinum analog with activity in colorectal cancer.
    Berg D
    Oncol Nurs Forum; 2003; 30(6):957-66. PubMed ID: 14603353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
    Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapeutic options in colon cancer: focus on oxaliplatin.
    Wilkes GM
    Clin J Oncol Nurs; 2002; 6(3):131-7. PubMed ID: 11998605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
    Sessa C; Del Conte G
    Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboplatin in the treatment of ovarian cancer.
    Alberts DS; Mason-Liddil N
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboplatin.
    Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics and safety profile of oxaliplatin.
    Extra JM; Marty M; Brienza S; Misset JL
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboplatin in the first-line chemotherapy of ovarian cancer.
    Alberts DS; Canetta R; Mason-Liddil N
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized single-agents trials in recurrent epithelial ovarian cancer.
    Sessa C; Marsoni S
    Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
    Ciccone MA; Maoz A; Casabar JK; Machida H; Mabuchi S; Matsuo K
    Expert Opin Investig Drugs; 2016 Jul; 25(7):781-96. PubMed ID: 27101098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining targeted therapies in ovarian cancer.
    Scambia G; Salutari V; Ferrandina G
    Lancet Oncol; 2014 Oct; 15(11):1179-81. PubMed ID: 25218905
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug therapy for gynaecological cancer in older women.
    van Rijswijk RE; Vermorken JB
    Drugs Aging; 2000 Jul; 17(1):13-32. PubMed ID: 10933513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a Phase II study.
    Salah-Eldin MA; Wahba HA; Halim AA
    Indian J Cancer; 2012; 49(1):169-75. PubMed ID: 22842184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.